上海之江生物科技股份有限公司 第五届监事会第二次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688317 证券简称：之江生物 公告编号：2023-025 表决结果：3 票同意、0 票反对、0 票弃权、0 票回避。 监事会认为：公司 2023 年半年度报告全文及摘要内容真实、准确、完整， 不存在任何虚假记载、误导性陈述或重大遗漏；公司 2023 年半年度报告全文及 摘要的编制和审议程序符合相关法律法规和《公司章程》等内部规章制度的规定， 公允地反映了公司 2023 年半年度的财务状况和经营成果等事项；半年度报告编 制过程中，未发现公司参与半年度报告编制和审议的人员有违反保密规定的行为。 2、审议通过《关于公司 2023 年半年度募集资金存放与实际使用情况的专项 报告的议案》 表决结果：3 票同意、0 票反对、0 票弃权、0 票回避。 监事会认为：公司 2023 年半年度募集资金存放与使用情况符合《上海证券 交易所科创板股票上市规则》、《上海证券交易所科创板上市公司自律监管指引 第 1 号——规范运作 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥84,348,212.48, a decrease of 89.59% compared to the same period last year[5] - Net profit attributable to shareholders was ¥6,026,571.66, down 97.81% year-on-year[5] - The net profit excluding non-recurring gains and losses was ¥7,015,965.17, reflecting a decline of 97.45% compared to the previous year[5] - The net cash flow from operating activities was -¥171,882,022.73, a decrease of 162.34% year-on-year[6] - Basic and diluted earnings per share were both ¥0.03, down 97.87% from the same period last year[6] - The total comprehensive income for Q1 2023 was ¥3,658,041.80, a decrease from ¥267,248,470.93 in Q1 2022, reflecting a decline of approximately 98.6%[20] - The total operating profit for Q1 2023 was ¥10,063,921.65, a significant drop from ¥324,239,329.48 in Q1 2022, reflecting a decline of about 96.9%[23] Research and Development - Research and development expenses totaled ¥14,504,728.20, an increase of 30.34% compared to the previous year[6] - R&D expenses accounted for 17.20% of operating revenue, up 15.83 percentage points year-on-year[6] - Research and development expenses increased to ¥14,504,728.20 in Q1 2023 from ¥11,128,219.98 in Q1 2022, marking an increase of about 30.7%[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,524,640,294.07, a decrease of 4.62% from the end of the previous year[6] - Cash and cash equivalents as of March 31, 2023, were RMB 2,923,264,994.00, down from RMB 3,147,723,751.88 at the end of 2022, showing a decrease of approximately 7.1%[14] - Accounts receivable decreased to RMB 204,565,453.68 from RMB 227,622,831.28, a decline of about 10.1%[14] - Inventory increased to RMB 516,133,617.18 from RMB 504,032,006.81, representing a growth of approximately 2.2%[14] - Total liabilities decreased to RMB 320,570,594.87 from RMB 543,439,647.94, a reduction of approximately 41.0%[16] - Shareholders' equity attributable to shareholders was ¥4,204,069,699.20, a slight increase of 0.09% compared to the previous year[6] - Shareholders' equity increased slightly to RMB 4,204,069,699.20 from RMB 4,200,411,657.40, reflecting a marginal growth[16] Business Strategy and Outlook - The company reported a significant decline in sales revenue due to changes in product sales structure[8] - The company reported a significant drop in both revenue and operating costs, indicating potential restructuring or changes in business strategy[18] - The company has not provided specific guidance for future performance or new product developments in this report[12] Cash Flow and Investments - The net cash flow from operating activities for Q1 2023 was -¥171,882,022.73, compared to ¥275,709,142.52 in Q1 2022, representing a decline of approximately 162.3%[23] - The company reported a net cash outflow from investing activities of -¥42,034,813.73 in Q1 2023, compared to -¥43,788,254.52 in Q1 2022, showing a slight improvement[24] - Cash and cash equivalents at the end of Q1 2023 were ¥2,923,264,994.00, down from ¥3,164,464,365.60 at the end of Q1 2022, indicating a decrease of approximately 7.6%[24] Foreign Exchange Impact - The company experienced a foreign exchange loss of -¥10,541,921.43 in Q1 2023, compared to -¥3,381,492.57 in Q1 2022, indicating a worsening of approximately 211.5%[24]

Financial Performance - The net profit attributable to shareholders for 2022 was RMB 760,273,479.93, with a total distributable profit of RMB 1,717,459,254.86 as of December 31, 2022[6]. - The company plans to distribute a cash dividend of RMB 12 per 10 shares, totaling RMB 230,589,598.80 (including tax) based on the total share capital of 194,704,350 shares[6]. - The total cash dividend for the year amounted to RMB 332,623,516.07, representing 43.75% of the net profit attributable to shareholders[7]. - The company's operating revenue for 2022 was CNY 2,326,255,117.23, representing a 15.23% increase compared to CNY 2,018,829,748.78 in 2021[24]. - The net profit attributable to shareholders of the listed company for 2022 was CNY 760,273,479.93, a slight increase of 0.23% from CNY 758,524,934.06 in 2021[24]. - The net profit after deducting non-recurring gains and losses was CNY 712,091,183.01, down 3.23% from CNY 735,871,022.81 in 2021[24]. - The company's total assets at the end of 2022 were CNY 4,743,851,305.34, an increase of 11.50% from CNY 4,254,679,653.54 at the end of 2021[24]. - The weighted average return on net assets for 2022 was 19.00%, a decrease of 3.13 percentage points from 22.13% in 2021[25]. - The basic earnings per share for 2022 were CNY 3.93, a decrease of 1.26% from CNY 3.98 in 2021[25]. - The net cash flow from operating activities for 2022 was CNY 584,971,135.46, a decrease of 8.87% from CNY 641,937,293.08 in 2021[24]. Share Repurchase and Dividends - The company has repurchased shares with a total expenditure of RMB 102,033,917.27 as of December 31, 2022[7]. - The company has not implemented any other forms of profit distribution, such as capital reserve transfers or stock dividends, for the current year[7]. - The total cash dividends distributed in 2022 amounted to RMB 332,623,516.07, including the amount for share repurchases[195]. Research and Development - Research and development expenses accounted for 4.50% of operating revenue in 2022, down from 5.39% in 2021[26]. - The company has developed over 400 products in molecular diagnostic reagents and instruments, making it one of the most comprehensive providers of infectious disease molecular diagnostic products in China[43]. - The company has established a comprehensive R&D platform and has developed core technologies such as automated nucleic acid extraction and multiplex real-time PCR technology[88]. - The company has ongoing projects in the respiratory pathogen detection field, with a total investment of ¥8,000,000, of which ¥3,986,670 was invested this period, achieving CE certification for four products[75]. - The company has a strong focus on R&D, with a total of 14 new applications and 6 patents granted during the reporting period[69]. Market and Product Development - The global in vitro diagnostic (IVD) market is projected to reach $127.4 billion in 2022, with expectations to grow to approximately $140 billion by 2027, driven by emerging markets like China and India[50]. - The molecular diagnostics sector is the fastest-growing sub-industry within IVD, with applications in infectious diseases, tumor diagnosis, and genetic disease diagnosis[50]. - The company aims to enhance its product offerings by developing new diagnostic kits, including blood screening nucleic acid test kits and tumor early screening gene test kits[142]. - The company is focusing on expanding its product offerings in high-risk virus detection, with ongoing development of automated extraction reagents and devices[79]. Operational Risks and Management - The company has outlined various operational risks and corresponding mitigation measures in the report[5]. - The company faces risks related to core technology leakage, new product development, and market competition, which could impact its competitive edge[96]. - The company emphasizes the importance of retaining high-quality technical talent to maintain its technological leadership and core competitiveness[98]. - The company is exposed to risks of intensified market competition and potential price declines for its diagnostic products due to increasing market entrants and regulatory changes[99]. Corporate Governance - The board of directors and management have confirmed the accuracy and completeness of the annual report[4]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not violated decision-making procedures for external guarantees[9]. - The company has established a compensation and assessment committee to evaluate and determine the compensation plans for senior management based on their specific roles[198]. Employee and Talent Development - The company employed a total of 435 staff, with 166 in technical roles and 132 in sales[185]. - The total number of R&D personnel increased to 166, accounting for 38.16% of the total workforce, up from 35.59% in the previous year[85]. - The total compensation for R&D personnel reached approximately 23.3 million RMB, with an average salary of 140,350 RMB[85]. - The company emphasizes talent development and has implemented multi-dimensional training programs for employees[188]. Future Outlook - The company provided a forward guidance of 1.5 billion in revenue for the next fiscal year, indicating a growth target of 25%[166]. - New product launches are expected to contribute an additional 200 million in revenue by the end of the year[167]. - The company aims to achieve international recognition for its product quality through enhanced media promotion and participation in influential projects[142]. - The company plans to strengthen its talent development and employee motivation strategies, focusing on high-level talent recruitment and internal training systems to support business growth and technological innovation[144].

证券代码：688317 证券简称：之江生物 公告编号：2023-008 上海之江生物科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 04 月 27 日(星期四) 上午 09:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 （一）会议召开时间：2023 年 04 月 27 日上午 09:00-10:00 （ 二 ） 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心网络互动 三、参加人员 董事长：邵俊斌先生 投资者可于 2023 年 04 月 20 日(星期四) 至 04 月 26 日(星期三)16:00 前 登录上证路演中心网站 ...

上海之江生物科技股份有限公司 投资者关系活动记录表 （2022 年 5 月） 证券简称：之江生物 证券代码：688317 | --- | --- | --- | |-------------------------|---------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：688317 证券简称：之江生物 上海之江生物科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2022 年第三季度报告 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 | 经营活动产生的现金 | 不适用 | 不适用 | 473,382,062.50 | | | 25.49 | | --- | --- | --- | --- | --- | --- | --- | | 流量净额 | | | | | | | | 基本每股收益（元/ | 0.79 | -28.83 | | 3.28 | | 3.14 | | 股） | | | | | | | ...

Financial Performance - The company reported a total revenue of 100 million CNY for the first half of 2022, representing a year-on-year increase of 20%[15]. - The company's operating revenue for the first half of 2022 was approximately RMB 1.48 billion, representing a year-on-year increase of 63.12%[21]. - Net profit attributable to shareholders for the same period was approximately RMB 477.90 million, a year-on-year increase of 23.56%[21]. - The basic and diluted earnings per share increased by 18.36% to RMB 2.45 compared to the same period last year[21]. - The net cash flow from operating activities increased by 178.73% to approximately RMB 314.20 million[21]. - The company has set a revenue guidance of 250 million CNY for the full year 2022, reflecting a growth target of 15%[15]. Market Expansion and Product Development - User data indicates a 30% increase in the number of active users of the company's products, reaching 500,000 users[15]. - The company plans to launch two new products in Q3 2022, targeting a market expansion of 15% in the next fiscal year[15]. - Market expansion efforts include entering two new international markets, aiming for a 10% contribution to total revenue by the end of 2022[15]. - The company has developed multiple series of instruments, including the EX series, iMag series, Autrax series, and Autra series, to meet diverse customer needs, achieving a transition from semi-automation to full automation[30]. - The company has developed and launched new products including COVID-19 antigen and neutralizing antibody detection kits[63]. Research and Development - Research and development expenses increased by 25%, totaling 10 million CNY, focusing on new technologies in molecular diagnostics[15]. - The total R&D investment for the current period was ¥32,038,652.78, a decrease of 2.26% compared to the previous year, with R&D investment as a percentage of operating income dropping from 3.61% to 2.17%[45]. - The company has over 400 products in its molecular diagnostic reagent portfolio, making it one of the most comprehensive in the field of infectious disease diagnostics in China[29]. - The company has developed core technologies such as automated nucleic acid extraction and high-throughput sequencing sample preprocessing technology, enhancing its R&D capabilities[56]. - The company has received 69 authorized patents, including 29 invention patents, indicating a strong focus on innovation and intellectual property[56]. Regulatory Compliance and Risks - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[15]. - The company faces risks related to product registration, which typically takes 3-5 years, potentially impacting future revenue recovery[68]. - There is a risk of intensified market competition as more manufacturers enter the molecular diagnostics sector, which could affect profitability[70]. - The ongoing COVID-19 pandemic has led to a temporary surge in demand for testing products, but future sales may not be sustainable[71]. Financial Position and Investments - The company maintains a strong cash position with 50 million CNY in cash reserves, ensuring liquidity for ongoing operations and investments[15]. - The total assets grew by 6.49% to approximately RMB 4.53 billion compared to the end of the previous year[21]. - The company made an equity investment of ¥30 million in Shanghai Kangshuai Cold Chain Technology Co., holding a 3.0994% stake post-investment[81]. - The total amount of non-current equity investments increased to ¥77,413,376.71, up from ¥74,968,373.45, indicating a growth of 3.25%[84]. Environmental Responsibility - The company has implemented strict environmental measures for waste management, including wastewater treatment through municipal systems and hazardous waste disposal by qualified firms[97]. - The company has not faced any administrative penalties related to environmental issues during the reporting period, demonstrating compliance with regulations[99]. - The company is committed to environmental responsibility, with measures in place to reduce carbon emissions, although specific actions were not detailed[100]. Shareholder Commitments and Governance - The company aims to avoid any activities that may harm the legitimate rights and interests of shareholders[107]. - The actual controller and major shareholders have pledged to adhere to a profit distribution policy that emphasizes reasonable returns to shareholders while ensuring sustainable development[110]. - The company will ensure compliance with relevant laws and regulations regarding share reduction by major shareholders[113]. - The company has established a commitment to maintain a stable and continuous profit distribution policy, with timely announcements in case of any violations[110]. Stock and Shareholder Structure - The total number of ordinary shareholders as of the end of the reporting period is 26,131[186]. - The top ten shareholders hold a total of 79,533,691 shares, representing 40.8% of the total shares[188]. - Shanghai Zhijiang Pharmaceutical Co., Ltd. is the largest shareholder, holding 64,969,560 shares, which accounts for 33.37% of the total shares[190]. - The company repurchased a total of 1,129,871 shares, accounting for 0.5803% of the total share capital, with a total expenditure of RMB 44,275,029.77[191].

Financial Performance - The company's operating revenue for Q1 2022 was ¥810,004,473.78, representing a year-over-year increase of 23.43%[5] - The net profit attributable to shareholders decreased by 12.90% to ¥275,435,800.66 compared to the same period last year[5] - Basic and diluted earnings per share were both ¥1.41, reflecting a decrease of 20.34% year-over-year[6] - Operating profit for Q1 2022 was ¥324,239,329.48, compared to ¥375,456,296.63 in Q1 2021, reflecting a decrease of 13.6%[16] - Net profit for Q1 2022 was ¥275,435,800.66, down 13.0% from ¥316,215,504.78 in Q1 2021[16] - Total comprehensive income for Q1 2022 was CNY 267,248,470.93, a decrease from CNY 278,047,895.24 in Q1 2021[17] Cash Flow - The net cash flow from operating activities increased by 53.78% to ¥275,709,142.52, primarily due to increased sales and cash collection[7] - Net cash flow from operating activities for Q1 2022 was CNY 275,709,142.52, up from CNY 179,287,670.20 in Q1 2021, representing a growth of 53.5%[20] - The company experienced a net cash outflow from investing activities of CNY -43,788,254.52 in Q1 2022, compared to a larger outflow of CNY -244,979,043.85 in Q1 2021[21] - Cash flow from financing activities in Q1 2022 resulted in a net inflow of CNY 1,948,049,340.89, significantly higher than the previous year[21] - The company received CNY 332,656,747.44 from investment recoveries in Q1 2022, with no such cash inflow reported in Q1 2021[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,549,113,091.56, an increase of 6.92% from the end of the previous year[6] - Current assets totaled ¥3,876,172,287.97, up from ¥3,552,844,091.97 at the end of 2021, indicating a growth of 9.1%[12] - Total liabilities increased to ¥454,455,652.71 from ¥427,270,685.63, marking a rise of 6.0%[14] - Cash and cash equivalents rose to ¥3,164,464,365.60, compared to ¥2,935,924,970.17 at the end of 2021, an increase of 7.8%[12] - The company’s equity attributable to shareholders increased to ¥4,094,657,438.85 from ¥3,827,408,967.91, reflecting a growth of 7.0%[14] Research and Development - Research and development expenses totaled ¥11,128,219.98, which is a decrease of 28.58% year-over-year, accounting for 1.37% of operating revenue[6] - Research and development expenses for Q1 2022 were ¥11,128,219.98, down 28.5% from ¥15,580,686.48 in Q1 2021[16] Shareholder Information - The total number of common shareholders at the end of the reporting period was 23,723[9] - The largest shareholder, Shanghai Zhijiang Pharmaceutical Co., Ltd., held 33.37% of the shares[9] Other Information - The company did not report any significant new product developments or market expansion strategies during this quarter[11] - The company reported a financial income of ¥33,230,483.14 in Q1 2022, significantly higher than ¥3,126,810.98 in Q1 2021[16] - The company paid CNY 49,768,936.33 in taxes during Q1 2022, down from CNY 105,516,974.81 in Q1 2021, indicating a reduction of 52.8%[20] - The company reported a net loss in other comprehensive income of CNY -8,187,329.73 for Q1 2022, compared to a loss of CNY -38,167,609.54 in Q1 2021[17]

Financial Performance - The net profit attributable to shareholders for 2021 was RMB 758,524,934.06, representing a 35.04% cash dividend payout ratio[5]. - The proposed cash dividend is RMB 13.65 per 10 shares (before tax), totaling RMB 265,771,437.75 based on a total share capital of 194,704,350 shares[5]. - As of December 31, 2021, the company's distributable profits amounted to RMB 1,298,787,749.90[5]. - The company has not yet achieved profitability since its listing[4]. - The company's operating revenue for 2021 was CNY 2,018,829,748.78, a decrease of 1.62% compared to the previous year[26]. - The net profit attributable to shareholders of the listed company was CNY 758,524,934.06, down 18.61% year-on-year[26]. - The net cash flow from operating activities decreased by 43.78% to CNY 641,937,293.08, primarily due to increased cash payments for goods and services[28]. - The total assets at the end of 2021 reached CNY 4,254,679,653.54, representing a growth of 126.36% compared to the beginning of the year[28]. - The company's net assets attributable to shareholders increased by 161.69% to CNY 3,827,408,967.91[28]. - Basic earnings per share decreased by 37.62% to CNY 3.98, while diluted earnings per share also fell by the same percentage[29]. - The weighted average return on equity decreased by 69.49 percentage points to 22.13%[29]. - The company reported a quarterly operating revenue of CNY 656,230,414.60 in Q1 2021, with a net profit of CNY 316,215,504.78[31]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 5.39%, up by 2.84 percentage points from the previous year[29]. - R&D investment reached CNY 108.79 million, accounting for 5.39% of operating revenue, with a year-on-year increase of 107.51%[39]. - The company has established a research and development team of 126 personnel, with a total R&D personnel compensation of 18,642,661.40 RMB, reflecting a significant increase from the previous year[94]. - The average salary of R&D personnel has increased to 147,957.63 RMB, up from 125,438.15 RMB in the previous year[94]. - The company is in the process of developing a monoclonal antibody drug targeting SARS-CoV-2, with a total investment of ¥50 million, of which ¥19.02 million has been invested to date[89]. - The company has developed a high-throughput sequencing sample preprocessing technology that improves the accuracy of bacterial identification to the species level[79]. - The company has developed core technologies such as automated nucleic acid extraction and high-throughput sequencing, which are crucial for its product offerings[71]. Market and Product Development - The company plans to expand its market presence and enhance product development in response to the ongoing challenges posed by the pandemic[28]. - The company has developed over 400 products, covering most legally mandated infectious diseases, and exports to multiple countries and regions[47]. - The company has launched several new products, including the portable real-time fluorescence quantitative PCR analyzer and the integrated nucleic acid detection system, addressing industry challenges and expanding application areas[49]. - The company has developed proprietary magnetic bead technology for nucleic acid extraction, allowing for simultaneous extraction of different types of nucleic acids from the same sample, breaking the monopoly of foreign manufacturers[64]. - The company has developed a reagent kit for intestinal flora testing, capable of detecting eight types of beneficial bacteria, with a total investment of 335.55 million RMB[90]. - The company has established partnerships with three leading hospitals to enhance clinical trials, which is expected to accelerate product development timelines[183]. Regulatory and Compliance - The report includes a standard unqualified audit opinion from Zhonghui Certified Public Accountants[5]. - The company has no non-operating fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures for external guarantees reported[9]. - The company has established a comprehensive quality management system covering R&D, procurement, production, sales, and service to ensure product quality stability[51]. - The company's governance practices are in compliance with relevant laws and regulations, with no significant discrepancies noted[168]. Risks and Challenges - The company has detailed various operational risks and corresponding mitigation measures in the report[4]. - The company faces risks related to core technology leakage, new product development, and the potential loss of key technical personnel, which could impact its competitive edge[104][106]. - The molecular diagnostics industry is experiencing intensified competition, with both domestic and international players, which may affect the company's operational performance and profitability[107]. - Future performance may be affected by the sustainability of demand for COVID-19 testing products as the pandemic situation evolves[115]. - The implementation of the "two-invoice system" poses long-term risks to the company's performance if strategic adjustments are not made[114]. Employee and Talent Development - The total number of employees increased to 354, up by 65 from the previous year, reflecting the company's focus on talent development[41]. - The employee composition includes 38 production staff, 128 sales personnel, 126 technical staff, 8 financial staff, and 54 administrative staff[197]. - The company emphasizes talent development and has increased training efforts through internal lectures, discussions, and external training[200]. - The company is committed to adjusting compensation plans based on regional and industry characteristics, as well as employee contributions[198]. Future Outlook - The company provided guidance for the next fiscal year, projecting revenue growth of 25% to $625 million[176]. - The company plans to enhance R&D investment to develop new products, including blood screening nucleic acid test kits and tumor early screening gene test kits[159]. - The company aims to expand its marketing network in major cities like Beijing, Guangzhou, and Wuhan to improve domestic market coverage[161]. - The company anticipates a continuous rapid growth phase requiring significant funding, planning to utilize various financing methods[164].

Financial Performance - The company's revenue for Q3 2021 was ¥573,540,299.36, representing a decrease of 4.34% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2021 was ¥215,960,907.48, down 19.33% year-on-year[5] - The basic earnings per share for Q3 2021 was ¥1.11, a decrease of 39.50% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses for Q3 2021 was ¥199,479,814.25, a decrease of 25.77% year-on-year[5] - Net profit for the third quarter of 2021 was ¥602,748,336.97, down from ¥695,539,406.89 in the same quarter of 2020, reflecting a decrease of approximately 13.3%[20] - The company reported a total comprehensive income of ¥572,393,149.79 for the third quarter of 2021, compared to ¥707,645,007.85 in the same quarter of 2020, indicating a decline of about 19.0%[21] Research and Development - Research and development expenses totaled ¥25,880,131.10 for Q3 2021, an increase of 187.71% year-on-year, accounting for 4.51% of revenue[6] - Research and development expenses for the first three quarters of 2021 were ¥58,658,299.41, significantly higher than ¥25,389,465.27 in 2020, representing an increase of about 130.9%[19] Assets and Equity - Total assets as of the end of Q3 2021 reached ¥4,086,799,124.44, a 117.43% increase from the end of the previous year[6] - The total equity attributable to shareholders at the end of Q3 2021 was ¥3,665,786,411.72, reflecting a 150.64% increase from the end of the previous year[9] - The company's total assets as of the end of the third quarter of 2021 amounted to ¥4,086,799,124.44, compared to ¥1,879,571,653.56 at the end of the same period in 2020, showing a significant increase of about 117.5%[19] - The company's equity attributable to shareholders reached ¥3,665,786,411.72, compared to ¥1,462,598,582.88 in the same period of 2020, marking an increase of approximately 150.5%[19] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥377,237,951.43, down 50.95% compared to the previous year[5] - The cash inflow from operating activities for the first three quarters of 2021 was CNY 1,518,159,879.48, an increase from CNY 1,416,223,487.96 in the same period of 2020, representing a growth of approximately 7.2%[22] - The net cash flow from operating activities decreased to CNY 377,237,951.43 in Q3 2021, down from CNY 769,124,283.43 in Q3 2020, indicating a decline of about 51%[23] - The total cash outflow from investing activities in Q3 2021 was CNY 500,888,576.14, significantly higher than CNY 75,113,809.10 in Q3 2020, reflecting an increase of approximately 570%[23] - The net cash flow from financing activities in Q3 2021 was CNY 1,634,636,679.05, compared to a negative cash flow of CNY 68,520,717.90 in Q3 2020, showing a substantial improvement[23] - The total cash and cash equivalents at the end of Q3 2021 reached CNY 2,712,942,397.63, up from CNY 861,152,810.40 at the end of Q3 2020, marking an increase of approximately 215%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,432[11] - The top ten shareholders hold a combined 33.3% of the shares, with Shanghai Zhijiang Pharmaceutical Co., Ltd. being the largest shareholder at 64,969,560 shares, or 33.3%[11] - The actual controller and chairman, Mr. Shao Junbin, plans to increase his shareholding by investing between ¥10 million and ¥15 million over a six-month period starting September 1, 2021, reflecting confidence in the company's future[14] Government Subsidies and Non-Recurring Gains - The company reported a total of ¥20,353,048.17 in government subsidies recognized in Q3 2021, contributing to non-recurring gains[7] Market and Product Development - The company has disclosed plans for market expansion and product development, focusing on enhancing its product portfolio and competitive edge[14] - The company received EU CE certification for several products, including COVID-19 testing kits and automated nucleic acid extraction instruments, enhancing its market competitiveness[14] Operating Costs - Total operating costs for the first three quarters of 2021 were ¥783,020,268, compared to ¥585,948,095 in 2020, indicating an increase of about 33.6%[19] Audit and Compliance - The company has not reported any audit opinion type applicable for the financial statements as of September 30, 2021[15] - The company did not apply the new leasing standards for the first time in 2021, which may impact future financial reporting[24] Related Party Relationships - The company has disclosed that it is unknown whether other shareholders have any related party relationships or concerted action relationships, aside from the known connections[12]